Clinical trial
3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast…
NCT00095888 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00095888 |
|---|---|
| Title | 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer |
| Official title | A Phase II Trial Of Gemcitabine And Triapine In Refractory Metastatic Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Drug, Other |
| Interventions | triapine, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study |
| Enrollment | 68 |
| Start date | Oct 1, 2004 |
| Primary completion | Jun 1, 2006 |
| First posted | Nov 9, 2004 |
| Last update posted | Jan 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: